Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. (XERS) filed this Form 8-K on July 15, 2026, reporting the completion of debt restructuring transactions. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics and Transaction Details
- Debt Reduction: The company eliminated all outstanding 8.00% Convertible Senior Notes due 2028 (2028 Notes).
- Exchange Transactions: Approximately $23 million in principal of 2028 Notes was exchanged for 5.0 million shares of common stock and $23 million in cash.
- Conversion Event: A separate holder converted $10.5 million in principal of 2028 Notes into approximately 3.6 million shares of common stock.
- Total Debt Eliminated: Approximately $33.5 million in aggregate principal amount.
- Total Equity Issued: Approximately 8.6 million shares of common stock.
- Liquidity Usage: The $23 million cash portion of the exchange consideration was funded with liquidity on-hand.
Material Changes Versus Prior Period
As of the completion of these transactions, no 2028 Notes remain outstanding, representing a complete removal of this specific debt instrument from the company's balance sheet. The filing does not provide comparative financial metrics (revenue, profit, or margins) for the prior period as this is a current event report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclaimers regarding the unregistered nature of the securities issued. The shares issued in the exchange were exempt under Section 4(a)(2) of the Securities Act, while shares from the conversion were exempt under Section 3(a)(9).
Investor Verification Checklist
- Verify the exact number of shares issued (5.0 million for exchange + 3.6 million for conversion) against the company's latest cap table.
- Confirm the impact of the $23 million cash outflow on the company's remaining cash and cash equivalents.
- Review the company's remaining debt obligations to ensure no other convertible notes or senior debt remain outstanding.
- Check for any subsequent filings regarding the registration rights or lock-up agreements for the newly issued shares.